|
Orthologous residues
|
|
GR (human): S203‑p, GR iso2 (human): S203‑p, GR (mouse): S212‑p, GR (rat): S224‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer, lung cancer
|
|
Relevant cell lines - cell types - tissues:
A549 (pulmonary), liver, lymph node, prostate, thyroid, U2OS (bone cell) [GR (human)]
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
dexamethasone
|
|
|
|
increase
|
|
|
RU-486
|
|
|
|
increase
|
|
|
prednisolone
|
|
|
|
increase
|
|
|
fluocinolone
|
|
|
|
increase
|
|
|
ZK299
|
|
|
|
no change compared to control
|
|
|
RU-486
|
dexamethasone
|
|
|
no effect upon treatment-induced increase
|
|
|
ZK299
|
dexamethasone
|
|
|
no effect upon treatment-induced increase
|
|
|
|
|